Clinical use of dalbavancin in Canada: the clear study final results.

Authors

George G Zhanel, Michael Silverman, Janhavi Bhalla, Melanie Baxter, Reza Rahimi, Maggie Wong, Yazdan Mirzanejad, Timothy MacLaggan, Kiarah Shchepanik, Heather Wise, Neal Irfan, Gabriel Girouard, Rita Dhami, Melissa Kucey, Vida Stankus, Kristin Schmidt, Sébastien Poulin, William Connors, Zain Chagla, Alex Serebryanskyy, Carlo Tascini, Jean-François Tessier, Yoav Keynan, Andrew Walkty, James A Karlowsky

Published in

Expert review of anti-infective therapy. Sep 25, 2026. Epub Sep 25, 2026.

Abstract

The CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry collected data on 160 Canadian patients who received dalbavancin between January 2023 and December 2025.
Clinicians used the web-based research data management program REDCap^™ to enter patient information into the CLEAR registry.
Dalbavancin was most frequently prescribed for acute bacterial skin and skin structure infections (55.6% of patients) and bone/joint infections (24.4%). Methicillin-resistant Staphylococcus aureus (MRSA) (55.6%) and methicillin-susceptible S. aureus (MSSA) (14.4%) were the most common pathogens treated. Dalbavancin treatment was most frequently initiated on a hospital ward (55.0%) or in the emergency department (26.9%). Dalbavancin therapy was chosen because it was a single-dose treatment (71.4%) or facilitated hospital discharge (16.9%) and was primarily administered without other antimicrobial agents (83.1%) as a single 1500 mg dose (63.0%). Microbiological success (pathogen eradicated/presumed eradicated) and clinical success (cure and/or improvement) rates were 93.8% (106/113) and 86.4% (89/103), respectively, for patients with known outcomes. One adverse event (hypersensitivity) was reported.
Dalbavancin has established itself as a unique and useful antimicrobial in Canada. CLEAR registry data confirm previously published peer-reviewed studies describing the efficacy and safety of dalbavancin in the treatment of various infections.

PMID:
42788820
Bibliographic data and abstract were imported from PubMed on 25 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.